Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.865 USD | -0.17% |
|
+5.33% | +11.91% |
07-04 | UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication | MT |
06-02 | ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients | MT |
Main competitors
P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|---|---|---|
-5.95x | - | 0.33x | - | - | - | - | 2.53B | ||
49.68x | 5.41x | -2.43x | 8.45x | 37.67x | 38.95x | -.--% | 34.72B | ||
-24.17x | 1.3x | -0.53x | 6.05x | -9.88x | -9.17x | -.--% | 28.05B | ||
17.15x | 3.01x | 0.67x | 4.22x | 11.65x | 13.67x | 1.71% | 28B | ||
-60.29x | - | -2.07x | - | -60.61x | -59.57x | -.--% | 19.22B | ||
-18.1x | 53.71x | 4.39x | 40.36x | -19.85x | -19.61x | -.--% | 18.36B | ||
13.51x | 2.11x | -0.91x | 2.67x | 7.53x | 8.14x | -.--% | 13.43B | ||
24.35x | 2.02x | 1.03x | 4.27x | 12.38x | 15.83x | -.--% | 13.32B | ||
2131.93x | 12.87x | -19.79x | 25.28x | 286.48x | 1255.09x | -.--% | 12.38B | ||
19.61x | 4.42x | 0.63x | 4.72x | 13.59x | 14.14x | -.--% | 12.32B | ||
-112.34x | 24.45x | -0.85x | 34.84x | -189.28x | -111.14x | -.--% | 9.78B | ||
412.8x | - | -3.69x | 22.37x | - | 266.25x | - | 9.56B | ||
-42.85x | 7.37x | 12.4x | 6.64x | -55.2x | -46.4x | -.--% | 7.32B | ||
-24.64x | 13.34x | 0.59x | 9.54x | -16.88x | -19.39x | -.--% | 6.99B | ||
30.56x | 5.55x | 0.31x | 10.19x | 31.91x | 34.53x | 0.43% | 6.1B | ||
23.73x | 6.1x | 0.96x | - | - | - | - | 5.91B | ||
-16.58x | 6.65x | -0.64x | - | -17.68x | -15.3x | -.--% | 5.89B | ||
57.71x | 1.94x | -2.43x | 3.51x | 15.95x | 29.15x | 0.31% | 5.8B | ||
-36.06x | 21.06x | 0.89x | 15.48x | -64.79x | -41.01x | -.--% | 4.86B | ||
Average | 128.42x | 10.71x | -0.59x | 13.24x | -1.06x | 79.66x | 0.15% | 12.87B | |
Weighted average by Cap. | 122.35x | 10.19x | -0.94x | 12.39x | 5.76x | 72.35x | 0.23% |
- Stock Market
- Equities
- IBRX Stock
- Sector ImmunityBio, Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition